Nutex Q3 Revenue Tops Estimates at $217.6M; Net Income Figure Conflicts With Filing
NUTX has more than doubled off its 52-week low of $83.99.
Summary
Nutex's Q3 revenue came in at $217.613 million, ahead of the $215 million IBES estimate, with gross profit of $101.526 million and EBIT of $77.098 million. The Reuters brief puts net income at $57.343 million, which does not square with the $40.2 million ($5.71 diluted) net income in the 10-Q filed minutes earlier — the gap needs reconciling before anyone trades off the number. Either way, the comparison that matters is year over year: the baseline shows revenue down from $267.8 million and net income down from $55.4 million a year earlier, so the beat is against a lowered bar. Nine-month earnings were also flattered by a $52.3 million one-time cut in arbitration-related costs, which is not recurring.
At the time of this announcement, NUTX was trading at $193.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $83.99 to $226.16. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.